SCHEMBL7070786

SCHEMBL7070786

O=C1NC(=O)C2(CCC(c3ccccc3)C2)N1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 2/20 0.43
DDB1 Q16531 1/20 0.42
ADAMTS5 Q9UNA0 5/20 0.40
TRPA1 O75762 1/20 0.40
PDE7A Q13946 1/20 0.39
CACNA1F O60840 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
HTR2A P28223 1/20 0.39
HRH1 P35367 1/20 0.39
SCN1A P35498 1/20 0.39
SCN4A P35499 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
CACNA1D Q01668 1/20 0.39
KCNH2 Q12809 1/20 0.39
CACNA1S Q13698 1/20 0.39
CACNA1C Q13936 1/20 0.39
SCN5A Q14524 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14117525 0.90 CRBN (0.49) CRBNDDB1ADAMTS5CACNA1FALDH1A1
SCHEMBL5358079 0.90 CRBN (0.49) CRBNDDB1ADAMTS5CACNA1FALDH1A1
SCHEMBL2046599 0.85 PDE7A (0.40) CRBNDDB1PDE7AAKR1A1AKR1B1
SCHEMBL14144951 0.85 PDE7A (0.40) CRBNDDB1PDE7AAKR1A1AKR1B1
SCHEMBL12588138 0.85 PDE7A (0.40) CRBNDDB1PDE7AAKR1A1AKR1B1
SCHEMBL10299843 0.85 PDE7A (0.40) CRBNDDB1PDE7AAKR1A1AKR1B1
SCHEMBL15954215 0.85 PDE7A (0.40) CRBNDDB1PDE7AAKR1A1AKR1B1
SCHEMBL2046597 0.85 PDE7A (0.40) CRBNDDB1PDE7AAKR1A1AKR1B1
SCHEMBL12588136 0.85 PDE7A (0.40) CRBNDDB1PDE7AAKR1A1AKR1B1
SCHEMBL14117579 0.76 HTT (0.41) CRBNADAMTS5PDE7AAKR1A1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296938-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE Pfizer Limited (GB) 2003-04-02 EP disclosed
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER, INC. 2002-05-02 US disclosed
WO-2002002513-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE PFIZER LIMITED (GB) 2002-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase ENGASE, ENPEP, CPN1 CRBN 3600/4885DDB1 3851/4885ADAMTS5 737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.